<DOC>
	<DOCNO>NCT02213926</DOCNO>
	<brief_summary>The purpose study characterize safety efficacy profile ACP-196 ( acalabrutinib ) subject relapse refractory Mantle Cell Lymphoma ( MCL ) .</brief_summary>
	<brief_title>An Open-label , Phase 2 Study ACP-196 ( Acalabrutinib ) Subjects With Mantle Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<criteria>Inclusion criterion : Men woman ≥ 18 year age . Pathologically confirm MCL , documentation monoclonal B cell chromosome translocation ( 11 ; 14 ) ( q13 ; q32 ) and/or overexpress cyclin D1 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 . Agreement use contraception study 30 day last dose study drug sexually active able bear beget child . Exclusion criterion : A lifethreatening illness , medical condition organ system dysfunction , investigator 's opinion , could compromise subject 's safety , interfere absorption metabolism ACP196 ( acalabrutinib ) , put study outcome undue risk Significant cardiovascular disease uncontrolled symptomatic arrhythmia , congestive heart failure , myocardial infarction within 6 month screen , Class 3 4 cardiac disease define New York Heart Association Functional Classification , correct QT interval ( QTc ) &gt; 480 msec . Malabsorption syndrome , disease significantly affect gastrointestinal function , resection stomach small bowel ulcerative colitis , symptomatic inflammatory bowel disease , partial complete bowel obstruction . Breast feeding pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Bruton tyrosine kinase inhibitor</keyword>
	<keyword>Btk</keyword>
	<keyword>Mantle Cell Lymphoma</keyword>
	<keyword>MCL</keyword>
	<keyword>ACP-196</keyword>
	<keyword>Acalabrutinib</keyword>
	<keyword>ACE-LY-004</keyword>
</DOC>